Literature DB >> 7791947

Somatosensory and visual evoked potentials in congenital muscular dystrophy: correlation with MRI changes and muscle merosin status.

E Mercuri1, F Muntoni, A Berardinelli, J Pennock, C Sewry, J Philpot, V Dubowitz.   

Abstract

Congenital muscular dystrophy comprises a heterogeneous group of disorders, that have in common an early onset and a dystrophic picture on the muscle biopsy. The "pure" form of congenital muscular dystrophy is not associated with severe mental retardation or structural changes in the brain, though white matter changes on brain imaging have been detected in a significant proportion of cases. In this study we evaluated the incidence of sensory abnormalities (somatosensory and visual evoked responses) in a group of 17 patients with "pure" congenital muscular dystrophy and correlated the results of the evoked responses with the presence or absence of white matter changes on brain magnetic resonance imaging. Our results show close correlation between the presence of MRI white matter changes and abnormalities in the sensory evoked potentials. Conversely, all patients with normal brain MRI had normal somatosensory evoked potentials (SEP). Visual evoked potentials were less sensitive than somatosensory evoked potentials in detecting abnormalities in children with white matter changes on MRI. With the recent discovery of deficiency in merosin expression in the skeletal muscle of a subgroup of patients with CMD, we also correlated the presence or absence of white matter changes and the SEP responses with the merosin status. The results indicate that all merosin-negative patients had abnormal SEP as well as abnormal MRI, whilst no patient with normal merosin expression had an abnormal scan or abnormal SEP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7791947     DOI: 10.1055/s-2007-979711

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

1.  Refinement of the laminin alpha2 chain locus to human chromosome 6q2 in severe and mild merosin deficient congenital muscular dystrophy.

Authors:  I S Naom; M D'Alessandro; H Topaloglu; C Sewry; A Ferlini; A Helbling-Leclerc; P Guicheney; J Weissenbach; K Schwartz; K Bushby; J Philpot; V Dubowitz; F Muntoni
Journal:  J Med Genet       Date:  1997-02       Impact factor: 6.318

2.  PCR based mutation screening of the laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy.

Authors:  P Guicheney; N Vignier; X Zhang; Y He; C Cruaud; V Frey; A Helbling-Leclerc; P Richard; B Estournet; L Merlini; H Topaloglu; M Mora; J P Harpey; C A Haenggeli; A Barois; B Hainque; K Schwartz; F M Tomé; M Fardeau; K Tryggvason
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

Review 3.  The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.

Authors:  K J Jones; G Morgan; H Johnston; V Tobias; R A Ouvrier; I Wilkinson; K N North
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

4.  Expression of laminin subunits in human fetal skeletal muscle.

Authors:  C A Sewry; M Chevallay; F M Tomé
Journal:  Histochem J       Date:  1995-07

5.  Merosin-deficient congenital muscular dystrophy (MDCMD): a case report with MRI, MRS and DTI findings.

Authors:  Janice J K Ip; Peter K T Hui; M T Chau; Wendy W M Lam
Journal:  J Radiol Case Rep       Date:  2012-08-01

6.  Congenital muscular dystrophy and severe central nervous system atrophy in two siblings.

Authors:  Q H Leyten; P G Barth; F J Gabreëls; K Renkawek; W O Renier; A A Gabreëls-Festen; H J ter Laak; M G Smits
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  Alterations of the retino-cortical conduction in patients affected by classical congenital muscular dystrophy (CI-CMD) with merosin deficiency.

Authors:  A P Tormene; C Trevisan; F Martinello; C Riva; E Pastorello
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 1.854

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.